Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-α antibody infliximab [1]

European Journal of Clinical Investigation

Volumn 34, Issue 9, 2004, Pages 641-642

  Yazdani Biuki, Babak ^a,b   Stelzl, H ^a   Brezinschek, H P ^a   Hermann, J ^a   Mueller, T ^a   Krippl, P ^a   Graninger, W ^a   Wascher, T C ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; INSULIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GLUCOSE HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4944258755     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01390.x     Document Type: Letter

References (9)

1. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002;32 (Suppl. 3):24-34.
2. Mandrup-Poulsen T. Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 2003;66:1433-40.
3. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001;60:349-56.
4. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
5. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-5.
6. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000;85:1316-9.
7. St Clair EW. Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis 2002;61 (Suppl. 2):ii67-9.
8. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 2003;37:1256-65.
9. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.